nicorandil 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
nicotinic acid or nicotinoyl alcohol derivatives 1919 65141-46-0

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • nicorandil
  • perisalol
  • sigmart
A derivative of the NIACINAMIDE that is structurally combined with an organic nitrate. It is a potassium-channel opener that causes vasodilatation of arterioles and large coronary arteries. Its nitrate-like properties produce venous vasodilation through stimulation of guanylate cyclase.
  • Molecular weight: 211.18
  • Formula: C8H9N3O4
  • CLOGP: 0.54
  • LIPINSKI: 0
  • HAC: 7
  • HDO: 1
  • TPSA: 97.04
  • ALOGS: -2.25
  • ROTB: 5

Drug dosage:

DoseUnitRoute
40 mg O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 4.20 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 0.50 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 4.06 µM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 75 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 1.40 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 8.90 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.76 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 3.60 hours Lombardo F, Berellini G, Obach RS

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
kinase-safety-class ACVR2A,ACVR2B,AKT2,AURKA,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK5,CDK9,CHEK1,DDR1,DYRK1B,EIF2AK3,EPHB4,ERBB2,FLT3,GRK2,GRK3,GSK3B,ITK,JAK1,JAK2,MAP3K21,MAP3K7,MAPK1,MAPK12,MAPK7,MAPK8,MAPK9,MAPKAPK2,MARK4,MET,MTOR,NTRK2,PAK4,PDK1,PDK2,PDK4,PDPK1,PIK3CB,PIK3CD,PIM2,PLK1,PRKCD,PRKDC,SIK2,SIK3,STK33,SYK,TEK,TTK,ULK1,ZAP70 55
kinase-selectivity-class AXL,BRAF,CDK9,DDR1,DYRK1B,EPHB4,ERBB2,GRK2,MAP2K6,MAPK7,PRKDC,SIK2,STK33,TEK,TTK 15
pfas-class PFAS structural alert (1 = True, 0 = False) 0

Approvals:

DateAgencyCompanyOrphan
Jan. 1, 1984 YEAR INTRODUCED

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Acute kidney injury 85.54 25.95 86 3833 320301 90304227
Cardiac failure 65.84 25.95 47 3872 109449 90515079
Upper gastrointestinal haemorrhage 53.49 25.95 24 3895 22952 90601576
Drug interaction 50.68 25.95 61 3858 276392 90348136
Acute coronary syndrome 44.59 25.95 17 3902 10796 90613732
Fixed eruption 43.99 25.95 11 3908 1719 90622809
Hyponatraemia 43.34 25.95 40 3879 133498 90491030
Bradycardia 41.41 25.95 32 3887 83815 90540713
Haemorrhage intracranial 39.03 25.95 17 3902 15145 90609383
Hypotension 38.47 25.95 58 3861 325339 90299189
Rhabdomyolysis 35.45 25.95 24 3895 51232 90573296
Renal impairment 35.01 25.95 32 3887 105389 90519139
Brain stem stroke 34.74 25.95 7 3912 411 90624117
Hypomagnesaemia 32.88 25.95 20 3899 35568 90588960
Cerebral infarction 32.70 25.95 18 3901 26578 90597950
Hyperkalaemia 30.35 25.95 24 3895 64940 90559588
Angina pectoris 28.67 25.95 19 3900 39141 90585387
Melaena 28.21 25.95 18 3901 34779 90589749
Large intestinal ulcer 26.94 25.95 9 3910 3908 90620620
Eyelid ptosis 26.15 25.95 11 3908 8995 90615533

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Postictal paralysis 57.05 19.31 13 6740 364 42614218
Interstitial lung disease 56.83 19.31 66 6687 78396 42536186
Cardiac failure 52.32 19.31 74 6679 106782 42507800
Melaena 50.89 19.31 45 6708 38701 42575881
Angina pectoris 46.82 19.31 40 6713 32856 42581726
Acute kidney injury 40.70 19.31 139 6614 367198 42247384
Cerebral infarction 38.55 19.31 35 6718 31134 42583448
Drug interaction 35.85 19.31 108 6645 266891 42347691
Intraventricular haemorrhage 33.53 19.31 15 6738 3869 42610713
Hepatic function abnormal 33.39 19.31 41 6712 51526 42563056
Lactic acidosis 32.61 19.31 38 6715 45223 42569359
Acute myocardial infarction 32.53 19.31 43 6710 58122 42556460
Altered state of consciousness 28.85 19.31 29 6724 29230 42585352
Haemoptysis 28.75 19.31 36 6717 46131 42568451
Prinzmetal angina 28.62 19.31 10 6743 1347 42613235
Hypotension 27.15 19.31 96 6657 257535 42357047
Muscle haemorrhage 26.54 19.31 13 6740 4112 42610470
Pneumonia aspiration 26.44 19.31 36 6717 50042 42564540
Drug ineffective 26.41 19.31 37 6716 630160 41984422
Chest pain 26.27 19.31 64 6689 139466 42475116
Hypomagnesaemia 25.85 19.31 27 6726 28461 42586121
Pericardial haemorrhage 25.24 19.31 12 6741 3557 42611025
Electrocardiogram QT prolonged 24.60 19.31 34 6719 47911 42566671
Coronary artery restenosis 24.18 19.31 8 6745 914 42613668
Cardiac failure chronic 23.19 19.31 16 6737 9585 42604997
Gastrointestinal haemorrhage 23.02 19.31 49 6704 97677 42516905
Prerenal failure 22.95 19.31 10 6743 2423 42612159
Eosinophilia 22.66 19.31 27 6726 32872 42581710
Bradycardia 22.65 19.31 45 6708 85439 42529143
Cardiac failure acute 22.34 19.31 18 6735 13615 42600967
Malaise 22.27 19.31 79 6674 212077 42402505
Haemorrhage subcutaneous 22.15 19.31 10 6743 2636 42611946
Hypovitaminosis 21.33 19.31 7 6746 779 42613803
Photosensitivity reaction 21.30 19.31 17 6736 12685 42601897
Muscle contractions involuntary 21.29 19.31 9 6744 2025 42612557
Renal impairment 21.20 19.31 51 6702 110177 42504405
Pemphigoid 20.64 19.31 16 6737 11451 42603131
Cardiorenal syndrome 20.46 19.31 7 6746 886 42613696
Ileal ulcer 20.07 19.31 7 6746 937 42613645
Gastric ulcer 19.67 19.31 19 6734 18243 42596339
Drug-induced liver injury 19.42 19.31 27 6726 38246 42576336
Inappropriate antidiuretic hormone secretion 19.32 19.31 18 6735 16523 42598059

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Acute kidney injury 123.54 18.55 222 10624 635208 109943245
Cardiac failure 107.28 18.55 111 10735 187515 110390938
Drug interaction 96.08 18.55 174 10672 500009 110078444
Melaena 82.44 18.55 62 10784 68695 110509758
Interstitial lung disease 77.02 18.55 81 10765 139253 110439200
Angina pectoris 76.52 18.55 57 10789 62238 110516215
Cerebral infarction 76.43 18.55 53 10793 51785 110526668
Upper gastrointestinal haemorrhage 71.01 18.55 50 10796 50046 110528407
Hepatic function abnormal 62.42 18.55 59 10787 89236 110489217
Bradycardia 61.48 18.55 76 10770 155441 110423012
Hyponatraemia 61.07 18.55 90 10756 217563 110360890
Acute myocardial infarction 59.80 18.55 56 10790 83721 110494732
Acute coronary syndrome 57.69 18.55 33 10813 23079 110555374
Renal impairment 57.35 18.55 81 10765 188364 110390089
Postictal paralysis 56.79 18.55 13 10833 608 110577845
Hypotension 56.19 18.55 144 10702 523705 110054748
Hypomagnesaemia 54.30 18.55 46 10800 60324 110518129
Pneumonia aspiration 51.74 18.55 51 10795 81182 110497271
Gastrointestinal haemorrhage 50.14 18.55 71 10775 165447 110413006
Lactic acidosis 47.81 18.55 52 10794 92759 110485694
Prinzmetal angina 44.22 18.55 14 10832 2255 110576198
Drug ineffective 42.78 18.55 52 10794 1520488 109057965
Electrocardiogram QT prolonged 42.64 18.55 53 10793 108907 110469546
Cerebral haemorrhage 41.76 18.55 41 10805 64927 110513526
Gastric ulcer 41.37 18.55 33 10813 39794 110538659
Ischaemic stroke 40.34 18.55 33 10813 41230 110537223
Haemorrhage intracranial 38.93 18.55 28 10818 28941 110549512
Blood pressure decreased 37.28 18.55 51 10795 115040 110463413
Rhabdomyolysis 36.97 18.55 52 10794 120349 110458104
Pemphigoid 35.91 18.55 23 10823 19684 110558769
Intraventricular haemorrhage 35.41 18.55 15 10831 5492 110572961
Haemoptysis 35.05 18.55 39 10807 71315 110507138
Hyperkalaemia 34.99 18.55 54 10792 135742 110442711
Ventricular fibrillation 34.14 18.55 30 10816 41283 110537170
Hypoglycaemia 33.96 18.55 49 10797 116055 110462398
Fall 33.31 18.55 132 10714 603350 109975103
Altered state of consciousness 32.70 18.55 34 10812 57592 110520861
Cardiac failure chronic 32.55 18.55 19 10827 13792 110564661
Pain 29.69 18.55 30 10816 954925 109623528
Angina unstable 29.50 18.55 19 10827 16413 110562040
Drug intolerance 29.17 18.55 3 10843 406509 110171944
Muscle haemorrhage 29.16 18.55 14 10832 6855 110571598
Hypokalaemia 28.18 18.55 58 10788 182390 110396063
Arthralgia 27.19 18.55 22 10824 779610 109798843
Orthostatic hypotension 27.16 18.55 33 10813 66216 110512237
Infusion related reaction 26.87 18.55 3 10843 381159 110197294
Pericardial haemorrhage 26.38 18.55 12 10834 5205 110573248
Pulmonary alveolar haemorrhage 25.99 18.55 19 10827 20131 110558322
Coronary artery restenosis 25.93 18.55 8 10838 1184 110577269
Anaemia 25.74 18.55 114 10732 546972 110031481
Weight increased 25.68 18.55 5 10841 419639 110158814
Fixed eruption 25.47 18.55 11 10835 4221 110574232
Lip swelling 25.40 18.55 28 10818 50639 110527814
Myocardial ischaemia 25.37 18.55 21 10825 26663 110551790
Cardiac failure acute 25.11 18.55 20 10826 24058 110554395
Kounis syndrome 24.92 18.55 12 10834 5913 110572540
Prerenal failure 24.92 18.55 11 10835 4448 110574005
Brain stem stroke 24.69 18.55 7 10839 774 110577679
Disseminated intravascular coagulation 24.58 18.55 25 10821 41261 110537192
Duodenal ulcer 24.27 18.55 18 10828 19496 110558957
Immune thrombocytopenia 24.13 18.55 19 10827 22475 110555978
Inappropriate antidiuretic hormone secretion 22.94 18.55 22 10824 33829 110544624
Haemorrhage subcutaneous 22.64 18.55 11 10835 5528 110572925
Eosinophilia 22.36 18.55 28 10818 57908 110520545
Circulatory collapse 21.97 18.55 24 10822 42969 110535484
International normalised ratio increased 21.63 18.55 34 10812 86738 110491715
Blood creatine phosphokinase increased 21.59 18.55 31 10815 73046 110505407
Nasopharyngitis 21.55 18.55 6 10840 394355 110184098
Abdominal discomfort 21.50 18.55 6 10840 393852 110184601
Dehydration 21.27 18.55 68 10778 279443 110299010
Chest pain 21.27 18.55 83 10763 376292 110202161
Pancytopenia 20.73 18.55 56 10790 209557 110368896
Myocardial infarction 20.72 18.55 53 10793 192030 110386423
Hypovitaminosis 20.37 18.55 7 10839 1453 110577000
Coagulation factor deficiency 20.20 18.55 5 10841 327 110578126
Arterial injury 19.86 18.55 6 10840 828 110577625
Labelled drug-drug interaction medication error 19.77 18.55 19 10827 29283 110549170
Ileus paralytic 19.67 18.55 13 10833 11724 110566729
Marasmus 19.37 18.55 7 10839 1684 110576769
Large intestinal ulcer 19.30 18.55 10 10836 5751 110572702
Shock 19.26 18.55 25 10821 53563 110524890
Muscle contractions involuntary 18.69 18.55 9 10837 4435 110574018
Head injury 18.57 18.55 22 10824 42995 110535458

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC C01DX16 CARDIOVASCULAR SYSTEM
CARDIAC THERAPY
VASODILATORS USED IN CARDIAC DISEASES
Other vasodilators used in cardiac diseases
MeSH PA D000889 Anti-Arrhythmia Agents
MeSH PA D000959 Antihypertensive Agents
MeSH PA D002317 Cardiovascular Agents
MeSH PA D014665 Vasodilator Agents
MeSH PA D014803 Vitamin B Complex
MeSH PA D014815 Vitamins
MeSH PA D018977 Micronutrients
CHEBI has role CHEBI:22587 antiviral agent
CHEBI has role CHEBI:35554 cardiovascular drug
CHEBI has role CHEBI:35620 vasodilator agent
CHEBI has role CHEBI:79085 potassium channel opener

Related Drugs by ATC class:

C01DX Other vasodilators used in cardiac diseases 18 drugs
benziodaronecarbocromencinepazetcloridaroldilazepefloxateetafenoneheptaminolhexobendineimolamineitramin tosilatelinsidomine show all 18 →

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Angina pectoris indication 194828000




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 10.97 acidic
pKa2 3.07 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
ATP-sensitive inward rectifier potassium channel 11 Ion channel IC50 5.89 WOMBAT-PK
ATP-sensitive inward rectifier potassium channel 1 Ion channel IC50 5.95 WOMBAT-PK
Atrial natriuretic peptide receptor 1 Enzyme EC50 7.20 WOMBAT-PK

External reference:

IDSource
N0000167327 NUI
D01810 KEGG_DRUG
C0068700 UMLSCUI
CHEBI:31905 CHEBI
CHEMBL284906 ChEMBL_ID
DB09220 DRUGBANK_ID
D020108 MESH_DESCRIPTOR_UI
47528 PUBCHEM_CID
2411 IUPHAR_LIGAND_ID
4933 INN_ID
260456HAM0 UNII
31748 RXNORM
005831 NDDF
319304004 SNOMEDCT_US
395809002 SNOMEDCT_US
260456HAM0 INXIGHT DRUGS

Pharmaceutical products:

None